Kidney Cancer
PRINCIPAL
PRospectIve ObservatioNal Study of real World Treatment Patterns and Treatment OutComes In PAtients with Advanced or Metastatic Renal CelL Carcinoma Receiving pazopanib
It is an international study aiming to collect information regarding the administration and treatment outcomes of patients with kidney cancer who are receiving pazopanib as their first-line therapy. This drug is an anti-angiogenic agent, approved in our country (as well as in most countries worldwide) for kidney cancer, and is already being administered to many Greek patients. The purpose of the study is to capture data from everyday medical practice concerning the use of this drug.
Patients can participate if they have advanced kidney cancer and are scheduled to start treatment with pazopanib within the next 30 days. As this is a registry study, the treatment and management of patients remain the exclusive responsibility of the treating oncologist and are in no way determined by the study protocol.
Study Centers - Responsible Persons
GNA ALEXANDRA (A. Bamiás 210 3381543)
SUNRISES
A randomized phase II study to explore the efficacy and feasibility of upfront rotations between SUNitinib and Everolimus versus sequential treatment of fiRst lIne Sunitinib and Second line EverolimuS until progression in patients metastatic clear cell renal cancer
This is an international study (Spain, France, Greece), which includes patients receiving first-line treatment for metastatic kidney cancer.
Main criteria for participation in the study
1. Advanced kidney cancer with evidence of clear cell histological type
2. Patients must not have received any prior treatment for metastatic kidney cancer
3. Satisfactory functional status of the patient
Treatment
The study is randomized, meaning that the patient will receive a treatment selected in a completely random and impersonal manner through a central process, common to all participating centers.
The treatment will be one of the following two regimens (with a 50% chance of receiving one or the other):
Sunitinib: Taken orally daily until the disease stops responding, and is the approved treatment you would receive if you were not participating in the study.
Sunitinib alternating with Everolimus: Everolimus is also an approved drug for the treatment of advanced kidney cancer recurrence and is an inhibitor of a molecular pathway that may play a role in the development of resistance to Sunitinib. Every 12 weeks, the drugs alternate in an attempt to prevent or slow the development of resistance to Sunitinib.
Study Centers - Responsible persons
General Hospital of Athens "Alexandra" (A. Bamia 210 3381543)